Prosecution Insights
Last updated: April 19, 2026
Application No. 18/555,956

ENZYMATICALLY-CLEAVABLE GLYCIDYL METHACRYLATE HYALURONIC ACID

Final Rejection §112
Filed
Oct 18, 2023
Examiner
ROBINSON, HOPE A
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
3y 5m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
700 granted / 1032 resolved
+7.8% vs TC avg
Strong +43% interview lift
Without
With
+43.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
70 currently pending
Career history
1102
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
47.0%
+7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1032 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. The Amendment filed on February 17, 2026, has been received and entered. Claim Disposition 3. Claims 2-3 and 6 have been cancelled. Claims 1, 4-5 and 7-15 are pending and are under examination. Claim objection 4. Claims 1, 4-5 and 7-15 are objected to for the following informalities: For clarity and precision of claim language it is suggested that claim 1 and 4, are amended to recite “a hydrogel comprising …” and “a composition comprising….”, because open language is better suited in reflecting the claimed embodiments. The dependent claims hereto are also included. For clarity it is suggested that claim 11 is amended to delete “involves”, because there is no description (i.e.,…….nerve injury is from a traumatic accident….). The dependent claims hereto are also included. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claims 1, 4-5 and 7-15 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1, 4 and the dependent claims hereto are indefinite for the recitation of “consisting of” which is closed language and the recitation of additional/further embodiments which reads instead on “comprising”. The dependent claims hereto are also included. Response to Arguments 6. Applicant’s comments have been considered in full. Withdrawn objections/rejections will not be discussed herein as applicant’s comments are moot. Note that new rejections and have been instituted based on amendments made to the claims for the reasons set forth above. Conclusion 7. No claims are presently allowable. 8. Applicant’s amendment necessitated the new/modified ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HOPE A ROBINSON whose telephone number is (571) 272-0957. The examiner can normally be reached 9-5pm on Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached on (408) 918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HOPE A ROBINSON/Primary Examiner, Art Unit 1652
Read full office action

Prosecution Timeline

Oct 18, 2023
Application Filed
Nov 19, 2025
Non-Final Rejection — §112
Feb 17, 2026
Response Filed
Mar 21, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595493
METHANATION METHOD IN A BIOREACTOR UNDER CONTINUOUS CELL-RETENTION CONDITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12584157
METHOD FOR PRODUCING GAMMA-GLUTAMYL-VALYL-GLYCINE AND/OR A SALT THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12559374
PROCESS FOR PRODUCING GRAPHENE DOPED WITH NITROGEN AND SULFUR
2y 5m to grant Granted Feb 24, 2026
Patent 12553069
Isopropylmalate synthase polypeptide variant and a method for producing L-leucine using the same
2y 5m to grant Granted Feb 17, 2026
Patent 12553071
GENETICALLY ENGINEERED STRAINS WITH REDUCED BYPRODUCT FORMATION
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+43.0%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 1032 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month